论文部分内容阅读
为寻求简便易行、安全有效适用于门诊治疗难治性多发性骨髓瘤(MM)患者的补救性方案,作者对56例难治性MM患者试用由VAD方案修改而来的(EACB)方案,包括复发性MM20例,原发耐药36例。前治疗有交替联合化疗(VMCP/VBAP)、MP或MP加α-干扰素,从初治直至病情恶化。EACB方案为:鬼臼乙叉甙(E)50mg/m~2iv(输注1小时)第1
In an effort to find a remedy that is simple, safe, and effective for outpatient treatment of patients with refractory multiple myeloma (MM), we randomized 56 patients with refractory MM to EVEB (modified from VAD) Including recurrent MM20 cases, primary resistance in 36 cases. Former treatment with alternating combined chemotherapy (VMCP / VBAP), MP or MP plus a-interferon, from the initial treatment until the condition deteriorated. EACB program is: Etoposide (E) 50mg / m ~ 2iv (infusion 1 hour) 1